Calculate your SIP ReturnsExplore

Supriya Lifescience Partners with US-based Plasma Nutrition; Stock Surges 7%

03 August 20233 mins read by Angel One
The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience the sole rights for manufacturing and marketing Ingredient Optimized Protein (ioProtein) in India.
Supriya Lifescience Partners with US-based Plasma Nutrition; Stock Surges 7%
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

On Wednesday, the shares of Supriya Lifescience closed at Rs 274.85, up by 6.16% from its previous closing of Rs 258.90 on the BSE. 

Supriya Lifescience has collaborated with Plasma Nutrition, Inc, a renowned United States-based company known for innovative consumer products located at Delaware. The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience the sole rights for manufacturing and marketing Ingredient Optimized Protein (ioProtein) in India

The primary purpose of this collaboration is to bring the optimized protein into the Indian market. ioProtein is a patented process (patent pending in the US) This revolutionary protein powder is designed for use as protein supplements and boasts a significant advantage, and it is highly bioavailable. This means that higher amounts of proteins are absorbed quickly by the body, providing consumers with a more effective and efficient protein supplement. 

During the term of the agreement, Supriya Lifescience will lead the manufacturing and marketing of ioProtein in India. This marks the introduction of a new category of protein powders in the Indian market, and it is relatively healthier compared to other popular protein powders available through various Gyms, general stores, and digital marketing channels. 

Established in 1987, Supriya Lifescience Ltd is a leading manufacturer of Active pharmaceutical Ingredients (API). Its state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India. Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). The company’s focus is to develop APIs and Intermediates for both Innovators, Generic companies and the company also partner exclusively as CMO. 

Today, the stock opened at Rs 257.05 and has touched a high and low of Rs 282.00 and Rs 254.50 respectively.  

The BSE group ‘B’ stock of face value Rs 2 has touched a 52 week high and low of Rs 381.70 and Rs 170.05, respectively. 

Last one week high and low of the scrip stood at Rs 282.00 and Rs 242.25 respectively. The current market cap of the company is Rs 2,212.07crore. 

The promoters holding in the company stood at 68.30%, while Institutions and Non-Institutions held 13.27% and 18.43% respectively. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet, and is subject to changes. Please consult an expert before making related decisions.

We're Live on WhatsApp! Join our channel for market insights & updates

Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.